ReviewCurrent oncology reports2016
Improving Systemic Chemotherapy for Bladder Cancer.
Review in Current oncology reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 41 citations in OpenAlex.
- Lipid metabolism subtypes reflects the prognosis and immune profiles of bladder cancer patients by NMF clustering and building related signature.Discover oncology · 2024Article
- Advances in Diagnosis and Therapy for Bladder Cancer.Cancers · 2022Review
- Predicting Prognosis and Distinguishing Cold and Hot Tumors in Bladder Urothelial Carcinoma Based on Necroptosis-Associated lncRNAs.Frontiers in immunology · 2022Article
- Effect of Traditional Chinese Medicine Combined with Bladder Perfusion with Hydroxycamptothecin on Color Ultrasound and Clinical Efficacy in Patients with Bladder Cancer Surgery.Evidence-based complementary and alternative medicine : eCAM · 2021Article
- The therapeutic and prognostic implications of molecular biomarkers in urothelial carcinoma.Translational cancer research · 2020Review
- miR-489-3p inhibits proliferation and migration of bladder cancer cells through downregulation of histone deacetylase 2.Oncology letters · 2020Article
- Magnesium in Combinatorial With Valproic Acid Suppressed the Proliferation and Migration of Human Bladder Cancer Cells.Frontiers in oncology · 2020Article
- CRISPR-Cas13a Targeting the Enhancer RNA-SMAD7e Inhibits Bladder Cancer Development BothFrontiers in molecular biosciences · 2020Article
- m6A RNA methylation regulators can contribute to malignant progression and impact the prognosis of bladder cancer.Bioscience reports · 2019Article
- Extracellular matrix protein 1 (ECM1) is associated with carcinogenesis potential of human bladder cancer.OncoTargets and therapy · 2019Article
- Downregulated Long Noncoding RNA PART1 Inhibits Proliferation and Promotes Apoptosis in Bladder Cancer.Technology in cancer research & treatment · 2019Article
- High LINC01605 expression predicts poor prognosis and promotes tumor progression via up-regulation of MMP9 in bladder cancer.Bioscience reports · 2018Article
- XPO1 inhibition by selinexor induces potent cytotoxicity against high grade bladder malignancies.Oncotarget · 2018Article
- Tumor-Specific Zr-89 Immuno-PET Imaging in a Human Bladder Cancer Model.Molecular imaging and biology · 2018Article
- LncRNA-SNHG16 predicts poor prognosis and promotes tumor proliferation through epigenetically silencing p21 in bladder cancer.Cancer gene therapy · 2018Article
- Lentivirus-mediated shRNA targetingOncoTargets and therapy · 2018Article
- Enhancer RNA - P2RY2e induced by estrogen promotes malignant behaviors of bladder cancer.International journal of biological sciences · 2018Article
- Naturally Occurring Canine Invasive Urinary Bladder Cancer: A Complementary Animal Model to Improve the Success Rate in Human Clinical Trials of New Cancer Drugs.International journal of genomics · 2017Review
- Patterns of Bladder Preservation Therapy Utilization for Muscle-Invasive Bladder Cancer.Bladder cancer (Amsterdam, Netherlands) · 2016Article
- Over-expression of long noncoding RNA BANCR inhibits malignant phenotypes of human bladder cancer.Journal of experimental & clinical cancer research : CR · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Systemic chemotherapy is integral to the management of muscle-invasive and metastatic bladder cancer (BCa). Neoadjuvant chemotherapy has been increasingly utilized for muscle-invasive BCa over the past several years, and several options for cisplatin-based regimens have emerged. Adjuvant chemotherapy may be considered for select patients who did not receive neoadjuvant therapy. Systemic chemotherapy added to radiotherapy is a critical component of a bladder-preserving approach and superior to radiotherapy alone. Cisplatin-based chemotherapy has been the mainstay for metastatic BCa for more than three decades. Novel targeted agents are in development fueled by the recent molecular characterization of BCa. Recent trials of immunotherapy have demonstrated the possibility of a less toxic and potentially more effective treatment for metastatic disease. It is an extremely exciting time for BCa research, and much needed improvements in systemic treatment are most certainly on the horizon.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.